Fasifree 10% w/v Oral Suspension

Țară: Irlanda

Limbă: engleză

Sursă: HPRA (Health Products Regulatory Authority)

Ingredient activ:

Triclabendazole

Disponibil de la:

Cross Vetpharm Group Limited

Codul ATC:

QP52AC01

INN (nume internaţional):

Triclabendazole

Dozare:

10 percent weight/volume

Forma farmaceutică:

Oral suspension

Tip de prescriptie medicala:

LM: Licensed Merchant as defined in relevant national legislation

Grupul Terapeutică:

Cattle, Sheep

Zonă Terapeutică:

triclabendazole

Indicații terapeutice:

Endoparasiticide

Statutul autorizaţiei:

Authorised

Data de autorizare:

2002-02-22

Caracteristicilor produsului

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fasifree 10% w/v Oral Suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension.
A white to off-white oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult, immature and early immature
stages of liver fluke (_Fasciola hepatica)_ susceptible to
triclabendazole.
4.3 CONTRAINDICATIONS
Do not use in animals known to be hypersensitive to the active
substance.
Each ml contains:
ACTIVE SUBSTANCE
Triclabendazole
100 mg
EXCIPIENTS
Methyl Parahydroxybenzoate (E218) Ph.Eur.
2.0 mg (preservative)
Propyl Parahydroxybenzoate (E216) Ph.Eur.
0.2 mg (preservative)
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_5_
_9_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and could
ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of
calibration of the dosing device.
Suspected clinical cases of re